Interleukin-36c (IL-36c) is a member of novel IL-1-like proinflammatory cytokine family that are highly expressed in epithelial tissues and several myeloid-derived cell types. Little is known about the role of the IL-36 family in mucosal immunity, including lung anti-bacterial responses. We used murine models of IL-36c deficiency to assess the contribution of IL-36c in the lung during experimental pneumonia. Induction of IL-36c was observed in the lung in response to Streptococcus pneumoniae (Sp) infection, and mature IL-36c protein was secreted primarily in microparticles. IL-36c-deficient mice challenged with Sp demonstrated increased mortality, decreased lung bacterial clearance and increased bacterial dissemination, in association with reduced local expression of type-1 cytokines, and impaired lung macrophage M1 polarization. IL-36c directly stimulated type-1 cytokine induction from dendritic cells in vitro in a MyD88-dependent manner. Similar protective effects of IL-36c were observed in a Gram-negative pneumonia model (Klebsiella pneumoniae). Intrapulmonary delivery of IL-36c-containing microparticles reconstituted immunity in IL-36c À / À mice. Enhanced expression of IL-36c was also observed in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome because of pneumonia. These studies indicate that IL-36c assumes a vital proximal role in the lung innate mucosal immunity during bacterial pneumonia by driving protective type-1 responses and classical macrophage activation.
INTRODUCTION
Type-1 cytokines are required for effective clearance of Streptococcus pneumoniae (Sp) 1 and Klebsiella pneumoniae (Kp) [2] [3] [4] in the lung. Lung dendritic cells (DCs) promote the development of type-1 immune responses via elaboration of interleukin-12 (IL-12) and IL-23. 5,6 IL-12 induces interferon-g (IFNg), which is important for effective innate immunity against a variety of bacterial pathogens. 7, 8 IL-23 drives type-1 and IL-17-mediated responses, which are protective in bacterial pneumonia. 3, 9 Survival is diminished with deficiencies in either IL-12 or -23 because of impaired bacterial clearance. 10 Early IFNg production by innate cells promotes cytokine and chemokine expression, which synergistically enhance alveolar macrophage (AM) and neutrophil (polymorphonuclear neutrophil) effector responses, and stimulate anti-microbial peptide (AMP) expression. [11] [12] [13] [14] IL-36 is the collective name for three novel members of the IL-1 superfamily of cytokines: IL-36a, -b, and -g. 15, 16 They share a common receptor, IL-36R, which bears significant homology to the classical IL-1 type-I receptor (IL-1R). 17 Binding of IL-36 to IL-36R recruits IL-1RAcP, a shared accessory protein with IL-1R, activating nuclear factor-kB and mitogen-activated protein kinases. IL-36Ra and IL-38 are IL-36R antagonists, which prevent the association of IL-36R with IL-1RAcP. 18, 19 IL-36 family members are expressed by a variety of cell types, with abundant expression in epithelial cells 16 and monocytes. 20, 21 IL-36 exerts proinflammatory effects, which is best characterized in models of psoriasis. IL-36 is highly expressed in the skin. 16, [22] [23] [24] [25] In animal models of psoriasis, IL-36 induces T-helper type-17 cytokines, AMPs, and other inflammatory cytokines. [24] [25] [26] [27] IL-36 also has effects on myeloid cells. DCs, macrophages, and T cells express IL-36R. 28 Recent data suggest that IL-36 activates DCs and promotes type-1 and T-helper type-17 responses. 28 For instance, IL-36a and -b promote T-helper type-1 polarization of naive T cells. Furthermore, incubation of peripheral blood monocytes with Aspergillus fumigatus in vitro induces IL-36g expression, and blockade of IL-36Ra enhances IFNg and IL-17 production. 29 In the lung, IL-36 family members are expressed in tracheal and bronchial epithelial cells and fibroblasts in response to various inflammatory stimuli. [30] [31] [32] [33] [34] However, full delineation of IL-36 cell sources, mechanisms of secretion, or IL-36-responsive cell types has yet to be determined.
In this study, we examined the role of IL-36g during experimental pneumonia due to the Gram-positive bacteria Sp and the Gram-negative pathogen Klebsiella pneumoniae (Kp). We demonstrate that IL-36g is selectively induced in the lung and secreted into the alveolar space predominantly in membrane-bound vesicles during infection. Moreover, IL-36g deficiency results in impaired lung bacterial clearance and enhanced dissemination, culminating in increased mortality. Finally, we demonstrate that IL-36g potently induces type-1 cytokines from DC during the evolution of bacterial pneumonia, promoting classical (M1) macrophage activation.
RESULTS

IL-36c, but not IL-36a or -b, is induced in the lung during pneumococcal pneumonia
To understand the role of IL-36 family members during Grampositive pneumonia, we first assessed IL-36 agonist induction after intrathecal Sp inoculation (3-5 Â 10 4 colony-forming unit (CFU)). IL-36 was measured in whole lungs of Sp-infected mice by quantitative reverse transcription-PCR(RT-PCR) at 4, 24, and 48 h after bacterial challenge. We observed a striking peak in induction of IL-36g mRNA (175-fold increase, Po0.01) 4 h after infection (Figure 1a ). The levels declined over 48 h, but remained significantly above that observed in uninfected lungs (Po0.05). Interestingly, we observed no induction of IL-36a or -b mRNA in whole lung after infection.
We next analyzed whole lung homogenates of Sp-infected mice for IL-36g protein by western blotting (Figure 1b ). There was no detectable constitutive IL-36g expression in uninfected animals. Maximal expression was observed at 24 h after Sp challenge. To quantitate IL-36g secretion into the alveolar space, mice were administered Sp intrathecally followed by bronchoalveolar lavage (BAL) at 24 and 48 h after infection. IL-36a and -g were measured by ELISA (enzyme-linked immunosorbent assay). No IL-36g was detected at any time points in cell-free BAL fluid (BALF) (Figure 1c ). We previously reported that IL-36g is secreted from activated pulmonary macrophages (PMs) in a nonclassical manner via packaging within microparticles (MPs), and, to a lesser extent, exosomes in vitro. 35 Interestingly, upon sonication of cell-free bronchoalveolar lavage fluid (BALF) to disrupt membrane-bound vesicles, we observed a significant increase in IL-36g detection in BALF at 24 and 48 h after Sp challenge, suggesting that IL-36g is contained within membrane-bound structures in the airspace in vivo. No IL-36a was detected at either time point in either unsonicated or sonicated BALF, which is concordant with a lack of mRNA induction.
IL-36c is released into the alveolar space within MPs in response to intrathecal Sp
To confirm that IL-36g was secreted in MPs in response to Sp infection, BALF was collected from mice 48 h after intrathecal Sp infection, and centrifuged as described in the Methods section to isolate MPs. The MP pellet was resuspended in the buffer, stained with Annexin V, and assessed by flow cytometry (Figure 1d ). Particles were present in BALF in the size range of MPs (100-500 nm) as compared with size-calibrated microspheres. After gating on DAPI (4',6-diamidino-2phenylindole)-negative particles to exclude those without intact membranes, 485% of particles stained positively for Annexin V, consistent with MPs. To establish the presence of IL-36g within the MP fraction, ultracentrifuged BALF from uninfected and Sp-infected mice consisting of the MP fraction was analyzed by western blotting (Figure 1e ). We detected IL-36g protein in the MP fraction of Sp-infected, but not Sp-uninfected, mice.
IL-36c deficiency results in increased mortality during pneumococcal pneumonia
To examine the impact of IL-36g on survival, animals were infected with Sp and observed until the time of death. We used models of both genetic deletion (Figure 2a ) and antibodymediated neutralization of IL-36g ( Figure 2b ). Using an approximate LD 0-25 dose of Sp in wild-type (WT) mice (1-5 Â 10 4 CFU), we observed 27% mortality in WT mice by 10 days. In comparison, mortality was significantly higher (64%) in IL-36g À / À mice (Po0.05). In antibody neutralization studies, administration of anti-mouse IL-36g antibody resulted in 40% mortality in Sp-infected mice, whereas all control immunoglobulin G (IgG)-treated mice survived (Po0.05).
IL-36c deficiency results in impaired lung bacterial clearance and increased dissemination
We next sought to explore mechanisms behind increased mortality in IL-36g-deficient mice. Animals, including both genetic deletion and antibody neutralization models, were challenged with intrathecal Sp (8 Â 10 4 CFU) and lungs and spleen were harvested at 24 and 48 h after infection (Figure 3) . At 24 h after infection, there was an B10-fold increase in bacterial CFU in the lungs of anti-IL-36g-treated mice as compared with control antibody-treated mice (Figure 3a) . By 48 h, Sp CFU were significantly reduced in WT animals but persistently elevated in anti-IL-36g-treated mice (44 log difference in CFU, Po0.001). Antibody neutralization also resulted in marked bacterial dissemination by 48 h, whereas no dissemination was observed in control IgG-treated mice (Po0.05, Figure 3b ). IL-36g À / À mice demonstrated similar defects in lung bacterial clearance at 48 h compared with WT mice, with nearly 7,000-fold greater CFU in IL-36g À / À mice as compared with WT mice (Po0.001, Figure 3c ). Moreover, increased dissemination was observed in IL-36g À / À mice compared with WT mice (1,500-fold difference in spleen CFU, Po0.05, Figure 3d ).
IL-36c deficiency impairs expression of type-1 and IL-17 cytokines during pneumococcal pneumonia
We next examined the effects of IL-36g deficiency on induction of type-1 and IL-17 cytokines during Sp infection. WT and IL-36g À / À mice were challenged with intrathecal Sp (5-8 Â 10 4 CFU), and lungs were harvested at 0, 4, 24, and 48 h after administration ( Figure 4 ). As compared with WT animals, we observed significant reductions in the early mRNA expression of the type-1 cytokines TNF-a (tumor necrosis factora) and IP-10/CXCL10 (IFNg-inducible protein 10/C-X-C motif chemokine 10) at 4 and 24 h in Sp-infected IL-36g À / À mice. Decreased expression of IL-23p19 and IL-17 was observed by 24 h. Reduced IL-12p40 and IFNg expression was also observed in IL-36g À / À mice by 48 h after infection.
Differences in bacterial clearance and dissemination are not due to impaired alveolar leukocyte influx or AMP expression
Additional experiments were performed to determine whether differences in survival, bacterial clearance, and dissemination were due to impairments in alveolar leukocyte influx during infection. Control and IL-36g-depleted/deficient mice were infected with intrathecal Sp (5-8 Â 10 4 CFU) and BAL leukocytes were enumerated at 8, 24, and 48 h after infection (Figure 5a,b ). We observed no significant differences in either total leukocyte or AM counts in anti-IL-36g antibody-treated animals as compared with control antibody-treated mice at 24 or 48 h. There was a modest but insignificant increase in neutrophils in anti-IL-36g antibody-treated mice compared with controls at 24 and 48 h, likely reflecting increased lung bacterial burden in IL-36g-depleted animals. Similarly, no significant differences were seen in total leukocytes, macrophages, or neutrophils at any time points following Sp administration in IL-36g À / À mice compared with controls ( Figure 5b ). After determining that leukocyte influx into the alveolar space was unaffected by IL-36g, we next assessed whether IL-36g influences whole lung cellularity, including interstitial leukocytes. WT and IL-36g À / À mice were infected with intrathecal Sp (5-8 Â 10 4 CFU). Whole lung tissue was collected and homogenized at 0, 24, and 48 h after infection, and leukocytes were enumerated ( Figure 5c ). Unstimulated IL-36g À / À showed a small but statistically insignificant decrease in both macrophages and neutrophils relative to WT mice. Following infection, there were again no significant differences in total leukocytes or leukocyte subsets between WT and IL-36g À / À mice. As with BAL neutrophils, we observed a modest but statistically insignificant increase in whole lung neutrophils in IL-36g À / À mice as compared with WT mice.
IL-36 family members have been reported to induce AMP expression in models of psoriasis. 24 To assess whether antimicrobial expression may be induced by IL-36g in lung cells, we treated isolated alveolar and interstitial PMs, type-II alveolar epithelial cells and bone marrow-derived DCs (BMDCs). Cells were treated in vitro with 50 ng ml À 1 recombinant IL-36g and cellular mRNA was analyzed for cathelicidin-related AMP and b-defensin-3 6 h after stimulation (Supplementary Figure S1 online). There were no significant differences in the expression of either AMP in any of the cell types tested. Moreover, we did not observe differences in mRNA expression of cathelicidin-related AMP and b-defensin mRNA in whole lung from WT and IL-36g mice in vivo during the course of Sp infection (data not shown).
Reduced ex vivo M1 macrophage activation in infected IL-36c À / À mice Having observed no differences in leukocyte influx or AMP expression, we next determined whether IL-36g influenced skewing of macrophage activation states. WT and IL-36g À / À mice were infected with intrathecal Sp (8 Â 10 4 CFU) and PMs were isolated 12 h after infection. This population of cells has been determined to be 495% macrophages based on F4/80 hi staining. There were no baseline differences in M1 activation markers in PMs from uninfected WT and mutant mice. At nitric oxide synthase in IL-36g À / À PMs ex vivo. There were no significant differences in the expression of alternative activation (M2) markers, Ym1 or arginase 1 (data not shown).
We next assessed whether IL-36g influences constitutive phagocytic function of macrophages. Bone marrow-derived macrophages (BMDMs) were isolated from uninfected WT, IL-36g À / À , and IL-36R À / À mice and incubated with FITClabeled Sp (Figure 6d ). Both IL-36g À / À and IL-36R À / À macrophages demonstrated significantly reduced phagocytosis as compared with WT BMDM.
IL-36c induces type-1 cytokines from DCs in a MyD88dependent manner
DCs promote the development of protective type-1 and IL-17 immune responses by elaboration of cytokines. 5, 6 Additionally, DCs highly express IL-36R. 28 We therefore examined whether IL-36g could directly induce type-1 cytokines from BMDC in vitro. IL-36R contains an intracellular Toll/interleukin-1 receptor domain similar to IL-1R and most Toll-like receptors (TLRs). Hence, it has been speculated, but not proven, that IL-36R signaling is MyD88-dependent. 17 To establish direct stimulatory effects and requirement for MyD88, murine BMDCs were isolated from WT and MyD88 À / À mice and treated with various doses of recombinant murine IL-36g ( Figure 7a ). We observed a dose-dependent increase in IL-12p40, IL-23p19, and TNF-a mRNA in response to IL-36g in WT BMDCs, with significant cytokine induction observed at doses as low as 5 ng ml À 1 . Induction of all cytokines was nearly completely mitigated in MyD88 À / À BMDCs. Cytokine induction in response to IL-36g was also impaired in IL-36R À / À BMDCs, but not TLR4 À / À BMDCs, confirming that the effect is IL-36R-specific and not due to endotoxin contamination.
We have shown that activated PMs secrete IL-36g within MPs and exosomes in vitro. 35 Figure 5 Effect of interleukin-36g (IL-36g) on inflammatory cell recruitment: (a) Wild-type (WT) mice were passively immunized with either a control immunoglobulin G (IgG) or anti-IL-36g IgG and infected with intrathecal (i.t.) Streptococcus pneumoniae (Sp). Total bronchoalveolar lavage (BAL) leukocytes were quantified, and macrophage and neutrophil counts were assessed by manual differential (no significant differences between groups at the same time point by one-way analysis of variance (ANOVA) with Sidak's multiple comparisons test, n ¼ 5 mice per group, representative of two experiments). (b) WT and IL-36g À / À were infected with i.t. Sp. Total leukocytes, macrophages, and neutrophils were assessed as above (no significant differences between groups at the same time point by one-way ANOVA with Sidak's multiple comparisons test, n ¼ 4-6 mice per group, representative of three experiments). (c) WT and IL-36g À / À were infected with i.t. Sp. Lungs were homogenized at the specified time points, and total leukocytes, macrophages, and neutrophils were assessed by manual differential (no significant differences between groups at the same time point by one-way ANOVA with Sidak's multiple comparisons test, n ¼ 3 mice per group per time point). Unstim, unstimulated. this, MPs were isolated from ATP-treated WT PMs (to stimulate maximal MP secretion), and then incubated with BMDCs (B10:1 MP-to-cell ratio) in the presence of either control or anti-IL-36g antibody. MPs from IL-36g À / À PMs served as an additional control. The number of MPs per condition was determined to be 2-3 Â 10 7 by flow cytometry, and did not differ significantly between WT and IL-36g À / À groups. BMDC mRNA was isolated at 6 and 24 h after incubation (Figure 7b) . In resting BMDCs, there was a minimal expression of cytokines, whereas BMDCs incubated with WT macrophage MPs in the presence of control IgG expressed significant levels of TNF-a mRNA at 6 h, and IL-12p40 and IL-23p19 mRNA at 6 and 24 h. In contrast, cytokine induction was markedly abrogated in BMDCs incubated with MPs treated with anti-IL-36g antibodies or MPs from IL-36g À / À PMs. No significant cytokine induction was observed from MyD88 À / À BMDCs treated with WT macrophage-derived MPs (data not shown).
Lung macrophage-derived MPs restore anti-bacterial immunity in IL-36c À / À mice To determine if macrophage-derived MP could restore anti-bacterial immunity in IL-36g-deficient mice, WT and IL-36g À / À mice were challenged with intrathecal Sp concomitant with cell-free MPs isolated from either WT or IL-36g À / À macrophages (2-3 Â 10 7 MPs per condition, Figure 8a ). As observed previously, IL-36g À / À mice administered vehicle control had impaired lung bacterial clearance as compared with WT/vehicle-treated animals (Po0.001). MPs isolated from either WT or IL-36g À / À PMs did not alter lung Sp CFU in WT mice. However, administration of MP from WT PM significantly reduced lung Sp CFU in IL-36g À / À mice, whereas no improvement in lung bacterial clearance was observed in IL-36g À / À mice administered MPs derived from IL-36g À / À PMs.
In addition to the improvement in lung bacterial clearance, administration of IL-36g-containing MPs also restored deficits in type-1 cytokine expression in IL-36g À / À mice in vivo. WT and IL-36g À / À mice were injected with either WT or IL-36g À / À MPs and Sp in the manner described above, and lungs were removed 48 h after infection. Cytokine concentrations were determined from whole lung homogenates by ELISA (Figure 8b) . WT mice expressed similar levels of cytokines, regardless of whether they received WT or IL-36g À / À MPs. IL-36g À / À mice that received IL-36g À / À MPs expressed significantly lower concentrations of IL-12p70, IL-23, and IFNg protein. However, cytokine expression in IL-36g À / À mice that received WT MPs was restored to similar levels as that observed in WT mice. 
IL-36c contributes to protective lung immunity against the Gram-negative pathogen Kp
Type-1 cytokines are required for effective innate immunity against certain Gram-negative pathogens, including Kp. 3, [7] [8] [9] We therefore examined the induction and biologic effects of IL-36g during experimental murine Kp pneumonia ( Figure 9 ). As with Sp, intrathecal administration of Kp (5-8 Â 10 3 CFU) induced IL-36g mRNA (Figure 9a ), albeit delayed relative to Sp, with IL-36g expression peaking at 48 h after infectious challenge (Figure 9b) . Although some IL-36g protein was detectable in unsonicated BALF 18 h after Kp infection, detection of IL-36g protein was substantially enhanced by sonication of cell-free BALF (Figure 9c) . Additionally, IL-36g À / À mice demonstrated impaired lung bacterial clearance and increased dissemination compared with WT mice (Figure 9d) . Similar effects were observed in anti-IL-36g antibody-treated mice (data not shown). Last, BALF of IL-36g À / À mice contained significantly less IL-12, IL-23, and IFNg 48 h after Kp administration, as compared with WT mice (Figure 9e ).
IL-36c is expressed in the lung and systemically during bacterial pneumonia-induced ARDS
To explore the relevance of our findings to human disease, we examined plasma and BALF from patients with acute respiratory distress syndrome (ARDS) due to bacterial pneumonia for the presence of human IL-36g protein by ELISA ( Figure 10 ). Plasma and BALF were sonicated to disrupt MPs and therefore maximize IL-36g detection. As compared with plasma and BALF from healthy controls, IL-36g levels were significantly increased in both plasma ( Figure 10a ) and BALF ( Figure 10b ) of pneumonia patients as early as days 0-3 after onset of ARDS. Increased plasma levels persisted as long as 28 days after ARDS onset, whereas BALF IL-36g levels were elevated up to 3 weeks. Additionally, we measured the IL-36g mRNA expression in adherence-purified AMs collected from a subset of pneumonia-induced ARDS patients (n ¼ 7) within 3 days of ARDS onset (Figure 10c ). As compared with AMs from healthy control subjects, there was an B15-fold increase of IL-36g mRNA levels in AMs of ARDS patients (Po0.05).
DISCUSSION
Our understanding of the role of IL-36 family members in innate immune responses is limited. Increasing evidence supports the importance of IL-36 in inflammatory disorders, such as psoriasis, where IL-36 induces T-helper type-17 cytokines, chemokines, AMPs, and other inflammatory cytokines. [24] [25] [26] [27] Considerably less is known about the effects of IL-36 in the lung. The intrathecal instillation of recombinant IL-36g and -a triggered production of inflammatory cytokines and alveolar neutrophilic influx in vivo, although doses administered were almost certainly supraphysiologic. 31, 32 Relevant to infection, incubation of PBMCs with Aspergillus fumigatus in vitro induced IL-36g, and blockade of IL-36Ra enhanced IFNg and IL-17 production. 29 In this study, we demonstrated that IL-36g is selectively produced in the lung in response to intrathecal Sp infection (Figure 1 ). Induction begins early during infection, with peak mRNA levels observed as early as 4 h after inoculation, and protein by 24 h. We have also shown that IL-36g is induced in response to the Gramnegative bacteria, Kp, although somewhat delayed relative to Sp infection. The reason for this delay is unclear, but may be related to the higher inoculum of Sp (B10-fold greater) as compared with that of Kp. We previously demonstrated that IL-36g is induced in PM and secreted in a nonclassical manner packaged within MPs and exosomes. 35 Herein, we have demonstrated that IL-36g is secreted into BALF of infected mice (Figure 1c ) and humans (Figure 10b) . Detection of IL-36g protein was greatly enhanced by sonication, supporting the notion that IL-36g is released into the alveolar space within membrane-bound vesicles. Flow cytometry confirmed the presence of intact MPs (Figure 1d) , and western blotting revealed IL-36g protein within the MP fraction of cell-free BALF (Figure 1e ). Collectively, our in vivo findings support our novel in vitro studies, which indicate that IL-36g is secreted into the alveoli within MPs in vivo in response to bacterial infection. This is in line with previous reports that IL-36 agonists lack a leader sequence and secretion is enhanced by purinergic receptor activation, which stimulates nonclassical secretion of proteins by promoting MP formation at the plasma membrane. [36] [37] [38] [39] IL-36g deficiency, either by genetic deletion or by antibody neutralization, resulted in significantly increased mortality during Sp pneumonia (Figure 2) . This was almost certainly attributable to marked impairment in lung bacterial clearance and enhanced bacterial dissemination in the absence of IL-36g ( Figure 3) . Similarly, IL-36g deficiency impaired lung bacterial clearance during Kp pneumonia (Figure 9) . Mortality in our studies was somewhat delayed relative to the finding of impaired bacterial clearance by 48 h after Sp challenge. This discrepancy is likely due, in part, to the decreased CFU inoculum used in mortality studies relative to other experiments. However, it is also known that mortality in pneumococcal pneumonia is not merely the result of lung bacterial burden and respiratory compromise but is also due to complications of bacteremia such as sepsis and multiple organ failure. [40] [41] [42] Mortality due to these complications would therefore be predicted to occur after the establishment of significant bacteremia. Indeed, our findings are compatible with reports of the natural history of pneumococcal pneumonia in the preantibiotic era, which reported the highest mortality occurring between the seventh and ninth days after the onset of infection. 43 Type-1 and IL-17 cytokines are required for effective lung mucosal immunity against Sp 1,5,6 and Kp. 3, 4, [7] [8] [9] These cytokines stimulate alveolar leukocyte recruitment, macrophage and neutrophil effector responses, and induce AMP expression. [11] [12] [13] [14] DCs promote the development of protective type-1 and IL-17 immune responses via elaboration of TNF-a, IL-12, and IL-23. 5, 6 Importantly, IL-36g directly induces these cytokines from BMDCs in a dose-dependent manner (Figure 7) . Furthermore, MPs from WT macrophages induces type-1 and IL-17 cytokines in BMDCs in vitro in an IL-36g-dependent manner, raising the possibility that PMs may network with DCs to drive proximal cytokine production via paracrine expression of IL-36g. Type-1 and IL-17-cytokine induction was diminished in IL-36g À / À mice, as compared with WT animals in response to either Sp or Kp infection. In Sp-infected IL-36g À / À mice, there were early impairments in TNF-a and IP-10/CXCL10 induction (Figure 4) , whereas reduction in the expression of IL-23p19, IL-12p40, IFNg, and IL-17 were delayed 24-48 h after infection.
IL-17 is associated with various proinflammatory immune effects, including leukocyte recruitment. 44 However, in this model impairment in bacterial clearance was not attributable to deficits in either monocyte/macrophage or polymorphonuclear neutrophil influx into the airspace or interstitium ( Figure 5) . In fact, there was a modest, but statistically insignificant, increase in BAL and whole lung neutrophils in IL-36g-deficient mice at 48 h, likely reflecting increased bacterial burden at that time point. This suggests that IL-36g-dependent IL-17 induction is less impactful than effects on type-1 cytokines in this model. Effects on bacterial clearance were not attributable to direct anti-microbial properties of IL-36, as IL-36g at doses as high as 100 ng ml À 1 did not exert direct bactericidal activity against either Sp or Kp, nor did IL-36g induce AMPs from PMs, BMDCs, or alveolar epithelial cells in vitro or in lung in vivo ( Supplementary Figure 1) .
We have observed that IL-36g induces type-1 cytokines during bacterial pneumonia, notably IFNg. IFNg is responsible for a variety of immune functions, including M1 polarization of macrophages. 45 Classically activated macrophages participate in key proinflammatory responses, enhanced antigen presentation, and pathogen clearance. Our studies indicate that IL-36g is required for IFNg and inducible nitric oxide synthase induction in PMs in vivo during pneumonia ( Figure 6) , which suggests that IL-36g promotes effective M1 activation during infection. Moreover, BMDM phagocytic function is significantly reduced in vitro in IL-36g À / À or IL-36R À / À macrophages (Figure 6d ). This suggests that IL-36g (and perhaps other IL-36 agonists) tonically regulate macrophage phagocytic function. The mechanism by which this occurs is uncertain, and is a focus of ongoing investigation. Collectively, our data suggest that impairment in bacterial clearance, and ultimately survival, in IL-36g-deficient mice is due to diminished type-1 cytokine induction and, in turn, lack of effective M1 macrophage polarization, along with inherent defects in phagocytic activity.
As IL-36g is primarily released from macrophages within MPs, we attempted to restore mucosal immunity in Sp-infected IL-36g À / À mice by administering MP directly into the lung. MP administration to infected WT mice did not significantly enhance lung bacterial clearance over vehicle alone (Figure 8a) . However, administration of WT MPs, but not IL-36g À / À MPs, substantially improved bacterial clearance in IL-36g À / À mice. Additionally, WT MPs, but not IL-36g À / À MPs, improved type-1 cytokine expression in IL-36g À / À mice (Figure 8b) . Thus, IL-36g within lung macrophage-derived MP is uniquely responsible for restoring immunity in IL-36g-deficient mice, to the exclusion of other bioactive proteins contained within the MP. This also suggests that MP delivery may be a viable therapeutic option to modulate pulmonary immune responses, similar to MP delivery being used to promote alveolar epithelial repair in an LPS-induced lung injury model. 46 The exact mechanism(s) by which IL-36 signals when contained within MPs (via cell surface receptor-mediated signaling, internalization, or transfer of genetic material) remains to be elucidated.
IL-36R, such as IL-1R, IL-18R, and most TLRs, contains an intracellular Toll/interleukin-1 receptor domain leading to speculation that IL-36R signaling requires association with MyD88. In this study, we have established that IL-36gmediated cytokine induction is, in fact, MyD88-dependent ( Figure 7a ). This effect was specific for IL-36R signaling and not due to endotoxin contamination, as we observed loss of cytokine induction in BMDCs isolated from IL-36R-deficient mice but unaltered cytokine expression in BMDCs isolated from TLR4 À / À mice (data not shown).
We also found considerable induction of IL-36g in humans with pneumonia-induced ARDS (Figure 10 ). IL-36g was elevated in both the alveolar space and in circulation, suggesting that IL-36g not only has a role in local immune responses to infection but also the systemic inflammatory changes seen in ARDS. As with murine pneumonia, AMs appear to be an important source of IL-36g in pneumonia-induced ARDS. Of note, there was considerable patient-to-patient heterogeneity in IL-36g levels, which is not unexpected based on the syndromic nature of ARDS and the fact that the population included a mix of patients with both Gram-positive and -negative infections. We have also observed elevated systemic and BAL levels of IL-36g in ARDS subjects with sepsis because of infections other than pneumonia (data not shown). Thus, it is unclear whether elevated BAL levels in these subjects were due to the systemic or local effects of bacterial infection, or a combination of the two. Moreover, in the context of concurrent acute lung injury, it is difficult to discern the precise contribution of infection to the expression pattern of IL-36 observed in these patients. The patient population was relatively small with a low mortality rate; thus, we were unable to correlate IL-36g levels with mortality. We did not specifically assess whether IL-36g was localized to MPs or exosomes in the ARDS patients, as plasma and BAL samples were sonicated before ELISA. Interestingly, leukocyte-derived MPs have previously been reported in the BALF of ARDS patients and positively correlated with favorable clinical outcome in these patients. 47 Taken together, our findings demonstrate an essential role for IL-36g in the lung in response to bacterial infection via induction of type-1 cytokine responses and M1 macrophage polarization. Currently, there is significant interest in the role of IL-36 family members in the pathogenesis of certain autoimmune diseases, especially psoriasis 16, 22, [24] [25] [26] [27] [48] [49] [50] and therefore potential targets of immunomodulation. The present observations strongly suggest that IL-36g deletion/inhibition may have adverse effects in the setting of infection, and has obvious implications to host defense mechanisms in other bacterial infections, as well as numerous respiratory pathogens that require vigorous protective type-1 responses, such as fungi and mycobacterium.
METHODS
Animals. Specific pathogen-free age-and sex-matched C57BL/6 mice (WT) and TLR4 À / À mice were purchased from The Jackson Laboratory (Bar Harbor, ME). IL-36g À / À mice on a C57BL/6 background were developed by the Mutant Mouse Regional Resource Center at the University of California Davis (Davis, CA). IL-36 R À / À mice on a C57BL/6 background were obtained from Amgen (Thousand Oaks, CA). These mice all displayed normal pulmonary development, were without obvious immune defects in the resting state, and reproduced normally. All mice were housed in specific pathogen-free conditions within the animal care facility (Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI) until the day of being killed.
Reagents. Carrier-free recombinant mouse IL-36a and -g was purchased from R&D Systems (Minneapolis, MN) for use with in vitro stimulation, antibody generation, and as ELISA standards. For human IL-36g ELISA generation, human recombinant IL-36g and human anti-IL-36g polyclonal antibodies were also purchased from R&D Systems.
Bacterial preparation. Kp strain 43816, serotype 2 was grown overnight in trypticase soy broth (Becton-Dickinson, Franklin Lakes, NJ) at 37 1C. Sp serotype 3, 6303 (American Type Culture Collection, Manassas, VA) was grown to mid-log phase in Todd-Hewett broth, washed in phosphate-buffered saline (PBS), and serially diluted in sterile saline. Bacterial concentration was determined by measuring absorbance at 600 nm, and plotting on a standard curve of known CFU values. The culture was then diluted to the desired concentration. Heat-killed bacteria were prepared by incubating cultures in a 65 1C water bath for 45 min.
Generation of rabbit anti-mouse polyclonal IL-36-specific antibody. Anti-IL-36g antibody was generated in New Zealand white rabbits immunized with recombinant mouse IL-36a and -g as described previously. 51 The antibody was purified and titered by ELISA against IL-36g coated onto 96-well plates. Purified IgG from nonimmunized rabbits was used as a control.
Intratracheal inoculation. Mice were anesthetized with intraperitoneal ketamine and xylazine. Under sterile conditions, the trachea was exposed, and a 30 ml inoculum was administered via sterile 27-gauge needle. The skin incision was closed with surgical staples.
Whole lung, spleen, and blood CFU determination. At designated time points, mice were killed by CO 2 asphyxiation. The thoracic cavity was opened under sterile conditions. Whole blood was aspirated into heparinized syringes from the right ventricle, serially diluted 1:10 with sterile PBS, and plated on nutrient agar (Becton-Dickinson) to determine CFU. The pulmonary vasculature was perfused with 1 ml sterile PBS containing 5 mM EDTA via the right ventricle. Whole lungs and spleen were removed and homogenized separately in 1 ml PBS with protease inhibitor (Boehringer Mannheim, Indianapolis, IN). Homogenates were serially diluted 1:10 in PBS and plated.
Bronchoalveolar lavage. BAL was performed as described previously. 12 Briefly, the trachea was exposed and intubated using 1.7-mm outer diameter polyethylene tubing. PBS containing 5 mM EDTA was instilled into the trachea in three-1 ml aliquots and aspirated by syringe suctioning. BALF was centrifuged at 1,800 r.p.m at 4 1C for 10 min. Supernatants were reserved for other experiments. Cell pellets were resuspended in 250 ml Gibco RPMI medium (Invitrogen, Carlsbad, CA). Cell counts and viability were determined using Trypan blue exclusion. Cytospin slides were prepared and stained with a modified Wright-Giemsa stain.
Murine PM isolation. PMs, including both alveolar and interstitial lung macrophages, were isolated from dispersed lung digest cells by adherence purification as described previously. 52 Macrophage purity has been determined to be 495% by forward and side scatter characteristics and F4/80 hi and CD11b staining.
In vitro phagocytosis assay. BMDMs were harvested from mice (C57BL/6; IL-36g À / À ; IL-36 R À / À ) and the ability of the BMDMs from each mouse to phagocytize via opsonin-independent pathways was examined using a 300:1 ratio (FITC-labeled Sp). Briefly, 2 Â 10 5 BMDMs were plated on a half-area black 96-well plate and incubated with supplemented medium overnight at 37 1C. The next day, the medium was changed to serum-free medium, and 10 ml FITC-labeled Sp was added to each well. After 2 h at 37 1C, Trypan blue was added to quench extracellular fluorescence, and phagocytosis was quantified by intracellular fluorescence as described previously. 53 Human ARDS sample preparation. Patients with ARDS enrolled in the Acute Lung Injury Specialized Center of Clinically Oriented Research (SCCOR) randomized trial of granulocyte-macrophage colony-stimulating factor administration in patients with ARDS conducted at the University of Michigan between July 2004 and October 2007 were studied. 54 ARDS was defined as acute onset of illness with: (1) PaO 2 /FiO 2 r300; (2) bilateral infiltrates consistent with pulmonary edema on chest radiograph; (3) requirement for positive pressure ventilation via endotracheal tube; (4) no clinical evidence of left atrial hypertension; (5) if measured, pulmonary arterial wedge pressure r18 mm Hg; and (6) the aforementioned criteria occurring together within a 24-h interval. For this study, only patients with a clinical diagnosis of pneumonia from the observational or placebo arms of the trial were analyzed (n ¼ 40). Subjects underwent serial bronchoscopy with BAL and peripheral blood collection after the onset of ARDS. BAL AMs were collected from seven ARDS patients. 54, 55 Serial blood and BAL samples were also collected from five healthy control subjects. Control subjects were o55-year-old lifelong nonsmokers taking no medications. Demographic and clinical data are summarized in Supplementary Table 1 .
Peripheral whole-blood samples were collected in heparin-containing Vacutainer tubes (Becton-Dickinson) and centrifuged (1,500 r.p.m. for 10 min at room temperature). Plasma was stored at À 80 1C. BALF obtained from control subjects and ARDS patients by bronchoscopy using standard technique 54, 55 was centrifuged (1,500 r.p.m. at 4 1C for 10 min). Cell-free supernatant was decanted and stored ( À 70 1C). Cells were resuspended and plated in Gibco RPMI medium. After 1 h, plates were washed with sterile PBS. Adherent macrophages were resuspended in Trizol reagent and stored ( À 20 1C). Cell differentials after adherence revealed 490% macrophages by morphology, and highly expressed both CD163 and CD14. mRNA expression of CD163 and CD14 by AM isolated from ARDS patients was not different than that from control patients (data not shown). BALF and plasma were sonicated (2 Â 10 s output, 140 Hz) before use in ELISAs.
MP isolation. PMs were cultured at a concentration of 5 Â 10 6 cells per tissue culture plate. Following stimulation, conditioned media was collected and centrifuged at 1,500 g for 30 min at 4 1C to remove cell debris and apoptotic bodies. The supernatant was stored at À 80 1C until further use up to a maximum of 2 weeks. Supernatants were thawed and ultracentrifuged at 25 000 g for 30 min at 10 1C (Beckman Coulter Life Sciences, Indianapolis, IN). MP-containing pellets were resuspended in RPMI.
Murine ELISAs for cytokine measurement. Cell-free BALF supernatants were analyzed for indicated cytokines using mouse DuoSet ELISA Kits (R&D Systems, Minneapolis, MN) as per the manufacturer's protocol.
Real-time quantitative RT-PCR. Gene expression was assessed using the ABI Prism 7000 Sequence Detection System (Applied Biosystem, Foster City, CA) as described previously. 52 Briefly, total cellular RNA from lungs was isolated, reversed transcribed into cDNA, and amplified using specific primers for indicated genes with b-actin serving as a control. Specific thermal cycling parameters used with the TaqMan One-Step RT-PCR Master Mix Reagents Kit (Thermo Fisher Scientific, Waltham, MA) are as follows: 30 min at 48 1C, 10 min at 95 1C, and 40 cycles involving denaturation at 95 1C for 15 s and annealing/extension at 60 1C for 1 min. Relative quantitation of mRNA levels was plotted as fold change compared with untreated control cells. Experiments were performed in duplicate.
Western immunoblotting. Cells or tissues were homogenized in RIPA buffer containing protease and phosphatase inhibitors. Protein concentrations were determined by Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, CA). Samples were electrophoresed in 4-12% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, transferred to nitrocellulose, and blocked with 5% skim milk in PBS. After incubation with primary antibodies, blots were incubated with an horse radish peroxidase-conjugated secondary antibody and bands visualized using ECL (SuperSignal West Pico Substrate; Pierce Biotechnology, Rockford, IL).
Flow cytometry. MPs isolated by ultracentrifugation were resuspended in 100 ml Annexin V-Binding Buffer (BD Pharmingen, San Jose, CA), and stained with Annexin V-PE as per the manufacturer's protocol. Samples were counted on a MoFlo Astrios (Beckman Coulter), and analyzed using the FlowJo Flow Cytometry Analysis Software (FlowJo, LLC, Ashland, OR). Calibrated microbeads were used to determine size of particles present.
Statistics. Statistical significance of all experiments was determined using a value of Pr0.05 considered significant. Specific statistical testing, including post hoc testing where appropriate, is described in the accompanying figure legends. Error bars represent mean ± s.e.m. All calculations were performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA).
Study approval. Animal studies were reviewed and approved by the University Committee on the Use and Care of Animals (University of Michigan). Human studies used protocols approved by the University of Michigan Institutional Review Board. Written informed consent was obtained from participants or their legal proxy for medical decision making before study inclusion.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
